TScan Therapeutics (NASDAQ:TCRX) Cut to Equal Weight at Morgan Stanley

Morgan Stanley cut shares of TScan Therapeutics (NASDAQ:TCRX) from an overweight rating to an equal weight rating in a report published on Friday, MarketBeat reports.

Several other research analysts also recently issued reports on the stock. Needham & Company LLC dropped their target price on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, November 4th. BTIG Research lowered shares of TScan Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 4th. HC Wainwright cut their price target on TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Wednesday, October 8th. Finally, Wedbush reiterated an “outperform” rating and set a $7.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, August 12th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, TScan Therapeutics presently has a consensus rating of “Hold” and an average price target of $6.60.

TScan Therapeutics Trading Down 2.7%

Shares of TCRX opened at $1.10 on Friday. The firm’s 50-day moving average price is $1.84 and its 200-day moving average price is $1.70. The company has a current ratio of 6.44, a quick ratio of 6.44 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $62.43 million, a price-to-earnings ratio of -0.98 and a beta of 1.00. TScan Therapeutics has a 1-year low of $1.02 and a 1-year high of $4.94.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Wednesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.07. TScan Therapeutics had a negative return on equity of 73.33% and a negative net margin of 1,692.96%.The firm had revenue of $2.51 million during the quarter, compared to analyst estimates of $1.98 million. Sell-side analysts anticipate that TScan Therapeutics will post -1.12 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Aberdeen Group plc increased its holdings in shares of TScan Therapeutics by 0.9% in the first quarter. Aberdeen Group plc now owns 891,448 shares of the company’s stock worth $1,230,000 after purchasing an additional 7,744 shares during the last quarter. Boothbay Fund Management LLC grew its holdings in TScan Therapeutics by 50.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock valued at $35,000 after buying an additional 8,121 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in TScan Therapeutics by 6.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock valued at $235,000 after buying an additional 9,676 shares in the last quarter. Catalyst Funds Management Pty Ltd bought a new stake in TScan Therapeutics in the 2nd quarter worth approximately $26,000. Finally, Letko Brosseau & Associates Inc. raised its holdings in shares of TScan Therapeutics by 24.4% during the 2nd quarter. Letko Brosseau & Associates Inc. now owns 95,875 shares of the company’s stock worth $139,000 after acquiring an additional 18,775 shares in the last quarter. Hedge funds and other institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.